Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Randomized phase II trials with a prospective control.

Sin-Ho Jung1

  • 1Department of Biostatistics and Bioinformatics, Duke University, Durham, NC 27710, USA. sinho.jung@duke.edu

Statistics in Medicine
|June 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Future oncology (London, England)·2026
Same author

Novel niclosamide stearate prodrug therapeutic shows potential efficacy against naturally occurring canine osteosarcoma in a clinical feasibility study.

American journal of veterinary research·2025
Same author

Design and analysis of individually randomized group-treatment trials with time to event outcomes.

Lifetime data analysis·2025
Same author

Low intensity focused ultrasound stimulation in stroke: A phase I safety & feasibility trial.

Brain stimulation·2025
Same author

Randomized Phase II Cancer Clinical Trials to Validate Predictive Biomarkers.

Biomedicines·2024
Same author

A Dunnett-Type Test and Its Sample Size Calculation for Comparing <i>K</i> ROC Curves with a Control.

Diagnostics (Basel, Switzerland)·2024
Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026
Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026
Same journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
Same journal

Beyond Fixed Thresholds: Optimizing Summaries of Wearable Device Data via Piecewise Linearization of Quantile Functions.

Statistics in medicine·2026
Same journal

A Causal Framework for Evaluating the Total Effect of Strategies Aiming to Expand Screening and to Improve Outcomes.

Statistics in medicine·2026
Same journal

Causal Effects on Nonterminal Event Time With Application to Antibiotic Usage and Future Resistance.

Statistics in medicine·2026
See all related articles

This study introduces novel two-stage designs for randomized phase II clinical trials. These designs enable early termination for ineffective experimental therapies, optimizing resource allocation and patient safety in drug development.

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Pharmaceutical Research

Background:

  • Phase II clinical trials are crucial for evaluating experimental therapies.
  • Early termination of ineffective trials is essential for resource optimization.
  • Existing designs may not fully address early stopping in randomized two-arm trials.

Purpose of the Study:

  • To propose and evaluate two-stage adaptive designs for randomized phase II trials.
  • To allow for early stopping of trials with unpromising experimental therapies.
  • To provide exact calculations for type I error and power.

Main Methods:

  • Utilized exact binomial distributions for precise calculation of design characteristics.
  • Defined minimax and optimal designs based on response probabilities and error constraints.

Related Experiment Videos

  • Developed analogs of Simon's designs for randomized two-arm and multi-arm trials.

    • Main Results:

    • The proposed designs allow for exact calculation of type I error and power.
    • Minimax and optimal designs were defined, satisfying prespecified error probabilities.
    • Methods were demonstrated with real-world phase II trial examples.

    Conclusions:

    • The proposed two-stage designs offer an effective approach for adaptive phase II clinical trials.
    • These designs facilitate early termination of ineffective treatments, improving trial efficiency.
    • The methodology is extendable to multi-arm trials, offering broad applicability.